Clearpoint Neuro vs Trisalus Life Sciences
Trisalus Life Sciences is the larger business, with $45.2m of revenue in fiscal 2025 against $37.0m for Clearpoint Neuro (1.2 times as much). Trisalus Life Sciences grew faster (53.4% against 17.8%). Clearpoint Neuro kept more of each dollar of sales as profit: a net margin of -69.1% against -86.9%.
| Latest fiscal year | Clearpoint NeuroCLPT, 2025 | Trisalus Life SciencesTLSI, 2025 |
|---|---|---|
| Revenue | $37.0m | $45.2m |
| Revenue growth | 17.8% | 53.4% |
| Net income | −$25.5m | −$39.2m |
| Operating margin | — | -59.7% |
| Net margin | -69.1% | -86.9% |
| Return on equity | -95.6% | — |
| Free cash flow | −$24.4m | −$18.9m |
| Cash | $45.9m | $20.4m |
| Total debt | $50.9m | $33.0m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 172 | 102 |
| Market value | $310m | $213m |
| Price vs our value range | — | — |
| Moat score | 30 (Weak) | — |
| Insider trades, 12 months | 0 buys, 9 sales | 12 buys, 18 sales |